- Home
- ZIP vs AVBP Comparison
ZIP vs AVBP Comparison
Compare ZIP & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIP
- AVBP
- Stock Information
- Founded
- ZIP 2010
- AVBP 2021
- Country
- ZIP United States
- AVBP United States
- Employees
- ZIP N/A
- AVBP N/A
- Industry
- ZIP Diversified Commercial Services
- AVBP
- Sector
- ZIP Consumer Discretionary
- AVBP
- Exchange
- ZIP Nasdaq
- AVBP NYSE
- Market Cap
- ZIP 972.5M
- AVBP 948.5M
- IPO Year
- ZIP 2021
- AVBP 2024
- Fundamental
- Price
- ZIP $7.08
- AVBP $27.10
- Analyst Decision
- ZIP Hold
- AVBP Strong Buy
- Analyst Count
- ZIP 6
- AVBP 5
- Target Price
- ZIP $9.80
- AVBP $36.80
- AVG Volume (30 Days)
- ZIP 459.9K
- AVBP 148.6K
- Earning Date
- ZIP 02-20-2025
- AVBP 02-02-2025
- Dividend Yield
- ZIP N/A
- AVBP N/A
- EPS Growth
- ZIP N/A
- AVBP N/A
- EPS
- ZIP 0.03
- AVBP N/A
- Revenue
- ZIP $498,903,000.00
- AVBP N/A
- Revenue This Year
- ZIP N/A
- AVBP N/A
- Revenue Next Year
- ZIP N/A
- AVBP N/A
- P/E Ratio
- ZIP $246.08
- AVBP N/A
- Revenue Growth
- ZIP N/A
- AVBP N/A
- 52 Week Low
- ZIP $6.84
- AVBP $14.35
- 52 Week High
- ZIP $15.35
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- ZIP 29.66
- AVBP 47.58
- Support Level
- ZIP $6.84
- AVBP $26.36
- Resistance Level
- ZIP $8.20
- AVBP $27.67
- Average True Range (ATR)
- ZIP 0.34
- AVBP 1.20
- MACD
- ZIP -0.00
- AVBP 0.13
- Stochastic Oscillator
- ZIP 16.22
- AVBP 78.34
About ZIP ZipRecruiter Inc.
ZipRecruiter Inc is an online employment marketplace. It was founded to make meaningful connections between job seekers and employers. It connects millions of job seekers with companies of all sizes. It is a two-sided marketplace for work that simplifies the job market for both job seekers and employers. Unlike traditional online job sites, ZipRecruiter works like a matchmaker curating job opportunities for job seekers, and candidates for employers.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.